In the ASCEND trial, which of the following regimens was associated with the highest 3-year progression-free survival (PFS) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)?

Acalabrutinib monotherapy
Idelalisib and rituximab
Bendamustine and rituximab

Congratulations to our October Winner!

B.C., Registered Nurse from NJ